Table 1 Clinico-pathological characteristics of 99 patients of ASCO/CAP Group 2
Characteristics | Value (%) |
|---|---|
Primary breast cancer | 93 (93.9%) |
With neoadjuvant therapy | 12 (12.9%) |
Without neoadjuvant therapy | 81 (87.1%) |
Recurrent or metastatic breast cancer | 6 (0.6%) |
Metastasis | 4 (66.7%) |
Recurrence | 2 (33.3%) |
Age (range 24-79y,median 56y) a | |
≤ 50 | 43 (46.2%) |
> 50 | 50 (53.8) |
Histological subtype b | |
ICONST | 77 (95.1%) |
Mixed ICONST and invasive micropapillary carcinoma | 1 (1.2%) |
Mixed ICONST and mucinous carcinoma | 1 (1.2%) |
Matrix producing carcinoma | 1 (1.2%) |
Invasive carcinoma with neuroendocrine differentiation | 1 (1.2%) |
Histological grade b | |
G2 | 28 (34.6%) |
G3 | 53 (65.4%) |
Pathologocal stage b | |
T1 | 37 (45.7%) |
T2 | 34 (42.0)% |
T3 | 3 (3.7%) |
Non-available | 7 (8.6%) |
Lymph node stage b | |
pN0 | 39 (48.1%) |
pN1 | 21 (25.9%) |
pN2 | 13 (16.0%) |
pN3 | 4 (4.9%) |
Non-available | 4 (4.9%) |
AJCC staging b | |
I | 25 (30.9%) |
II | 32 (39.5%) |
III | 15 (18.5%) |
Non-available | 9 (11.1%) |
ER a | |
Positive | 73 (78.5%) |
Negative | 20 (21.5%) |
PR a | |
Positive | 64 (68.8%) |
Negative | 29 (31.2%) |
HER2-IHC a | |
Negative (0,1+) | 25 (26.9%) |
Equivocal (2+) | 68 (73.1%) |
Ki67 a | |
> 30% | 43 (46.2%) |
≤ 30% | 50 (53.8%) |
Immunohistochemical surrogate subtype a | |
Lumina A-Like | 25 (26.9%) |
Lumina B-Like | 48 (51.6%) |
TNBC | 20 (21.5%) |
Surgery b | |
Modified radical mastectomy | 57 (70.4%) |
Simple mastectomy +Sentinel lymph node biopsy | 12 (14.8%) |
Conservative surgery +Sentinel lymph node biopsy | 8 (9.9%) |
Non-available | 4 (4.9%) |
anti-HER2 therapy a | |
Yes | 48 (51.%) |
No | 43 (46.2%) |
Non-available | 2 (2.2%) |